national
Moderna Shares Surge Following Successful Clinical Trial of Personal Cancer Vaccine
Just the facts
The clinical study demonstrated that combining Moderna's personalized cancer vaccine with Merck's immunotherapy drug Keytruda significantly reduced the risk of recurrence or death in high-risk melanoma patients. Following the announcement of the trial results, Moderna's stock price experienced a sharp increase on financial exchanges. The joint pharmaceutical partners plan to submit the clinical trial data to global regulatory agencies to apply for formal market authorization.
Why this is news
Biotechnology firm Moderna announced successful phase 3 clinical trial results for its experimental personalized mRNA melanoma vaccine developed in partnership with Merck.
Sources
This summary is compiled strictly from the original reporting below.